Biotie Enters Into a Licensing Agreement With Somaxon Pharmaceuticals for the North American Rights to nalmefene
Turku, Finland, November 12 (ots/PRNewswire) - - The Partnership Agreement on the First Indication (Pathological Gambling) Could be Valued at up to USD 13.2 Million Plus Royalties - Somaxon to Initiate a Phase III Clinical Development Program in Pathological Gambling Biotie Therapies Corp. and Somaxon ...
mehr